AzTrials
AzTrials

Depression, PostpartumPhase 3NCT04442503

A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)

A Phase 3 study testing SAGE-217 in people with Depression, Postpartum, run by Biogen at 82 sites in 3 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo. Read more about this study

Who is it for?
Ages 18 to 45 years, women only
Conditions the study is for
Depression, Postpartum
What is being tested?
SAGE-217
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
200 participants
Where
82 sitesin 3 countries
Study dates
8 Jun 2020to 12 Apr 2022
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Participant has ceased lactating or agrees not to provide breastmilk to her infant(s) from just prior to receiving the investigational product (IP) on Day 1 until 7 days after the last dose of IP.
  • Participant has had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for Diagnostic and DSM-5 Clinical Trial Version (SCID-5-CT).
  • Participant is ≤12 months postpartum at screening and Day 1.

Who cannot join

  • Participant is at significant risk of suicide or has attempted suicide associated with the current episode of PPD.
  • Participant has active psychosis per investigator assessment.
  • Participant has a medical history of nonfebrile seizures.
  • Participant has a medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder.
  • Participant has a history of sleep apnea.
  • Note: Other protocol-defined inclusion/exclusion criteria applied.

Trial locations and contacts

82 sites in 3 countries.

82 sites in 3 countries

United States68 sites
  • Sage Investigational Site

    Allentown, Pennsylvania, 18104

  • Sage Investigational Site

    Alpharetta, Georgia, 30022

  • Sage Investigational Site

    Anaheim, California, 92805

  • Sage Investigational Site

    Atlanta, Georgia, 30331

  • Sage Investigational Site

    Aurora, Colorado, 80045

  • Sage Investigational Site

    Beachwood, Ohio, 44122

  • Sage Investigational Site

    Bellevue, Washington, 98007

  • Sage Investigational Site

    Bellflower, California, 90706

  • Sage Investigational Site

    Bentonville, Arkansas, 72712

  • Sage Investigational Site

    Beverly Hills, California, 90212

  • Sage Investigational Site

    Boston, Massachusetts, 02114

  • Sage Investigational Site

    Boynton Beach, Florida, 33435

  • Sage Investigational Site

    Brooklyn, New York, 11229

  • Sage Investigational Site

    Chapel Hill, North Carolina, 27599

  • Sage Investigational site

    Charleston, South Carolina, 29425

  • Sage Investigational Site

    Charlotte, North Carolina, 28211

  • Sage Investigational Site

    Costa Mesa, California, 92627

  • Sage Investigational Site

    Dallas, Texas, 75231

  • Sage Investigational Site

    Decatur, Georgia, 30030

  • Sage Investigational Site

    Denver, North Carolina, 28037

  • Sage Investigational Site

    Detroit, Michigan, 48201

  • Sage Investigational Site

    Flowood, Mississippi, 39232

  • Sage Investigational Site

    Fort Worth, Texas, 76104

  • Sage Investigational Site

    Glen Oaks, New York, 11004

  • Sage Investigational Site

    Hialeah, Florida, 33012

  • Sage Investigational Site

    Hoffman Estates, Illinois, 60169

  • Sage Investigational Site

    Houston, Texas, 77058

  • Sage Investigational Site

    Idaho Falls, Idaho, 83404

  • Sage Investigational Site

    Imperial, California, 92251

  • Sage Investigational Site

    Jacksonville, Florida, 32256

  • Sage Investigational Site

    Las Vegas, Nevada, 89102

  • Sage Investigational Site

    League City, Texas, 77573

  • Sage Investigational Site

    Lemon Grove, California, 91945

  • Sage Investigational Site

    Lincolnwood, Illinois, 60712

  • Sage Investigational Site

    Marlton, New Jersey, 08053

  • Sage Investigational Site

    Mayfield Heights, Ohio, 44124

  • Sage Investigational Site

    Miami, Florida, 33133

  • Sage Investigational Site

    Miami Springs, Florida, 33166

  • Sage Investigational Site

    Miramar, Florida, 33029

  • Sage Investigational Site

    Moosic, Pennsylvania, 18507

  • Sage Investigational Site

    New Orleans, Louisiana, 70115

  • Sage Investigational Site

    New York, New York, 10036

  • Sage Investigational SIte

    North Canton, Ohio, 44720

  • Sage Investigational Site

    North Chesterfield, Virginia, 23235

  • Sage Investigational Site

    Norwalk, California, 90650

  • Sage Investigational Site

    Norwich, Connecticut, 06360

  • Sage Investigational Site

    Oceanside, California, 92056

  • Sage Investigational Site

    Oklahoma City, Oklahoma, 73112

  • Sage Investigational Site

    Orange, California, 92866

  • Sage Investigational Site

    Orange, California, 92868

  • Sage Investigational Site

    Orlando, Florida, 32801

  • Sage Investigational Site

    Orlando, Florida, 32807

  • Sage Investigational Site

    Pensacola, Florida, 35202

  • Sage Investigational Site

    Pinellas Park, Florida, 33872

  • Sage Investigational Site

    Pompano Beach, Florida, 33060

  • Sage Investigational Site

    Providence, Rhode Island, 02904

  • Sage Investigational Site

    Redlands, California, 92374

  • Sage Investigational Site

    Richardson, Texas, 75080

  • Sage Investigational Site

    Saint Charles, Missouri, 63304

  • Sage Investigational Site

    San Antonio, Texas, 78229

  • Sage Investigational Site

    San Bernardino, California, 92408

  • Sage Investigational Site

    Savannah, Georgia, 31405

  • Sage Investigational Site

    Scottsdale, Arizona, 85258

  • Sage Investigational Site

    Sherman Oaks, California, 91403

  • Sage Investigational Site

    St Louis, Missouri, 63125

  • Sage Investigational Site

    St Louis, Missouri, 63128

  • Sage Investigational Site

    Torrance, California, 90502

  • Sage Investigational Site

    Wichita, Kansas, 67226

Other trials in United States

Spain9 sites
  • Sage Investigational Site

    Barcelona, 8003

  • Sage Investigational Site

    Barcelona, 8035

  • Sage Investigational Site

    Barcelona, 8041

  • Sage Investigational Site

    Collado Villalba, 28040

  • Sage Investigational Site

    Madrid, 28031

  • Sage Investigational Site

    Oviedo, 33011

  • Sage Investigational Site

    Sabadell, 8208

  • Sage Investigational Site

    Valladolid, 47012

  • Sage Investigational Site

    Vigo, 36213

Other trials in Spain

United Kingdom5 sites
  • Sage Investigational Site

    Headington, Oxford, OX3 7JX

  • Sage Investigational Site

    Maidstone, ME16 9NW

  • Sage Investigational Site

    Morpeth, Northumberland, NE61 2NU

  • Sage Investigational Site

    Preston, Lancashire, PR2 8DW

  • Sage Investigational Site

    Runwell, Essex, SS11 7XX

Other trials in United Kingdom

About this study

Official title: A Randomized, Double-Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of SAGE-217 in the Treatment of Adults With Severe Postpartum Depression

The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.

Read the detailed description

This study was previously posted by Sage Therapeutics. In November 2023, sponsorship of the trial was transferred to Biogen.

Being tested
SAGE-217, Placebo
Keywords
SAGE-217, Postpartum depression
Medical subject headings
Depression, Postpartum

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SAGE-217Drug

    SAGE-217 oral capsules.

  • PlaceboDrug

    SAGE-217 matched-placebo oral capsules.

Study groups in NCT04442503
Study groupRoleWhat they receive
PlaceboPlacebo comparatorParticipants received SAGE-217 matched-placebo capsules, orally, once daily for 14 days.
Receives: Drug: Placebo
SAGE-217 50 mgExperimentalParticipants received SAGE-217, 50 mg, capsules, orally, once daily for 14 days.
Receives: Drug: SAGE-217

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15

    The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. Mixed Model for Repeated Measures (MMRM) was used for the analysis.

    Measured: Baseline and Day 15

Secondary outcomes (11)
  1. Change From Baseline in the 17-item HAM-D Total Score

    The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. MMRM was used for the analysis.

    Measured: Baseline, Days 3, 28 and 45

  2. Change From Baseline in Clinical Global Impressions - Severity Scale (CGI-S) Score

    The CGI-S is a 7-point Likert scale to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who had the same diagnosis. A participant was assessed on severity of mental illness at the time of rating as 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7= extremely ill participants. A lower score indicates a better outcome. A negative change from baseline indicates improvement. MMRM was used for the analysis.

    Measured: Baseline and Day 15

  3. Percentage of Participants With HAM-D Response

    The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. HAM-D response was defined as a ≥50% reduction in HAM-D total score from baseline.

    Measured: Days 15 and 45

  4. Percentage of Participants With HAM-D Remission

    The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of 17 individual items related to the following symptoms: depressed mood (sadness, hopeless, helpless, worthless), feelings of guilt, suicide, insomnia (early, middle, late), work and activities (slowness of thought and speech; impaired ability to concentrate; decreased motor activity), retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=none/absent and 4=most severe. The total score is the sum of the 17 individual items, ranges from 0 to 52; where a higher score indicates more depression. Negative change from baseline indicates improvement. HAM-D remission was defined as having a HAM-D total score of ≤7.

    Measured: Days 15 and 45

  5. Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response

    The CGI-I employs a 7-point Likert scale to measure the overall improvement in the participant's condition posttreatment. The investigator rated the participant's total improvement whether or not it is due entirely to drug treatment. Response choices include 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse. The CGI-I was only rated at posttreatment assessments. By definition, all CGI-I assessments are evaluated against baseline conditions. CGI-I response was defined as having a CGI-I score of "very much improved" or "much improved."

    Measured: Day 15

  6. Change From Baseline in Hamilton Rating Scale for Anxiety (HAM-A) Total Score

    The 14-item HAM-A was used to rate the severity of symptoms of anxiety. Each 14-items were defined by a series of symptoms, and measured both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). The HAM-A total score was calculated as the sum of the 14 individual item scores. The scoring for HAM-A is calculated by assigning scores of 0 (not present) to 4 (very severe), with a total score range of 0 to 56 where <17 indicated mild severity, 18 to 24, mild to moderate severity, and 25 to 30, moderate to severe severity. A negative change from baseline in HAM-A total score indicated improvement.

    Measured: Baseline and Day 15

  7. Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score

    The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. It includes questions on the following symptoms: apparent sadness; reported sadness; inner tension; reduced sleep; reduced appetite; concentration difficulties; lassitude; inability to feel; pessimistic thoughts; and suicidal thoughts. Each item is rated on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change from baseline in MADRS total score indicated improvement.

    Measured: Baseline and Day 15

  8. Change From Baseline in HAM-D Subscale

    17-item HAM-D scale is used for severity of depression. HAM-D subscales: Core subscale(depressed mood, feelings of guilt, suicide, work and activities, and retardation/20x100; Anxiety subscale[anxiety(psychic and somatic), somatic symptoms (gastrointestinal and general), hypochondriasis, and insight loss of weight]/18x100; Bech-6 subscale(depressed mood, feelings of guilt, work and activities, retardation, anxiety psychic, and somatic symptoms general)/22x100; Maier score(depressed mood, feelings of guilt, work and activities, retardation, agitation, and anxiety psychic)/24x100. Each item was scored in range of 0 to 2 or 0 to 4 (0=none to 2 or 4=severe), higher score=more depression. 4 Subscale scores were calculated as sum of individual rating scores related to each subscale, divided by total possible score within subscale, multiplied by 100. Scores were transformed to scale of 0 to 100, with higher scores=more severe depression. Negative CFB=improvement. MMRM was used for analysis.

    Measured: Baseline and Day 15

  9. Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the Edinburgh Postnatal Depression Scale (EPDS) Total Score

    The EPDS is a self-rated depressive symptom severity scale specific to the perinatal period which consists of 10 individual items. Each item is rated on a 4-point scale ranging from 0 to 3 points. The EPDS total score is calculated as the sum of the 10 individual item scores, ranging from 0 points to 30 points with a higher score indicating more depression. A negative change indicates improvement.

    Measured: Baseline, Days 3, 8,15, 21, 28 and 45

  10. Change From Baseline in Self-Reported Measures of Depressive Symptoms, as Assessed by the 9-item Patient Health Questionnaire (PHQ-9) Score

    The PHQ-9 is a self-rated depressive symptom severity scale to monitor severity over time for newly diagnosed participants or participants in current treatment for depression. Scoring was based on participants responses to 9 specific questions as follows: 0 = not at all; 1 = several days; 2 = more than half the days; and 3 = nearly every day. The score were calculated as the sum of the 9 individual item scores. The PHQ-9 total score was categorized as follows: 1 to 4 = minimal depression, 5 to 9 = mild depression, 10 to 14 = moderate depression, 15 to 19 = moderately severe depression; and 20 to 27 = severe depression. The PHQ-9 total score ranges from 1 to 27 with a higher score indicating more depression. A negative change from baseline indicates reduced depression. MMRM was used for the analysis.

    Measured: Baseline, Days 3, 8,15, 21, 28 and 45

  11. Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE is defined as an AE with onset after the start of IP, or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study.

    Measured: Up to Day 45

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jun 2020
  2. Study start8 Jun 2020
  3. Primary completion15 Mar 2022
  4. Study completion12 Apr 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
200 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04442503
Sponsor's protocol ID
217-PPD-301
Other IDs
2020-001424-34
Status last verified
Nov 2023
First submitted
18 Jun 2020
Last updated
30 Nov 2023
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Publications

  • Deligiannidis KM, Meltzer-Brody S, Maximos B, Peeper EQ, Freeman M, Lasser R, Bullock A, Kotecha M, Li S, Forrestal F, Rana N, Garcia M, Leclair B, Doherty J. Zuranolone for the Treatment of Postpartum Depression. Am J Psychiatry. 2023 Sep 1;180(9):668-675. doi: 10.1176/appi.ajp.20220785. Epub 2023 Jul 26.

    PubMed 37491938

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing SAGE-217 in people with Depression, Postpartum, run by Biogen at 82 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 82 sites in United States, Spain, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 22 Jun 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15 (time frame: Baseline and Day 15). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04442503, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in